193 related articles for article (PubMed ID: 24236980)
1. Nature as a source of metabolites with cholinesterase-inhibitory activity: an approach to Alzheimer's disease treatment.
Pinho BR; Ferreres F; Valentão P; Andrade PB
J Pharm Pharmacol; 2013 Dec; 65(12):1681-700. PubMed ID: 24236980
[TBL] [Abstract][Full Text] [Related]
2. Alkaloids as a source of potential anticholinesterase inhibitors for the treatment of Alzheimer's disease.
Konrath EL; Passos Cdos S; Klein LC; Henriques AT
J Pharm Pharmacol; 2013 Dec; 65(12):1701-25. PubMed ID: 24236981
[TBL] [Abstract][Full Text] [Related]
3. Natural products as sources of new lead compounds for the treatment of Alzheimer's disease.
Huang L; Su T; Li X
Curr Top Med Chem; 2013; 13(15):1864-78. PubMed ID: 23931437
[TBL] [Abstract][Full Text] [Related]
4. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease.
Sahoo AK; Dandapat J; Dash UC; Kanhar S
J Ethnopharmacol; 2018 Apr; 215():42-73. PubMed ID: 29248451
[TBL] [Abstract][Full Text] [Related]
5. An overview on natural cholinesterase inhibitors--a multi-targeted drug class--and their mass production.
Orhan IE; Orhan G; Gurkas E
Mini Rev Med Chem; 2011 Sep; 11(10):836-42. PubMed ID: 21762104
[TBL] [Abstract][Full Text] [Related]
6. Coumarins as cholinesterase inhibitors: A review.
de Souza LG; Rennã MN; Figueroa-Villar JD
Chem Biol Interact; 2016 Jul; 254():11-23. PubMed ID: 27174134
[TBL] [Abstract][Full Text] [Related]
7. Withanolides: Biologically Active Constituents in the Treatment of Alzheimer's Disease.
Khan SA; Khan SB; Shah Z; Asiri AM
Med Chem; 2016; 12(3):238-56. PubMed ID: 26527154
[TBL] [Abstract][Full Text] [Related]
8. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
Eskander MF; Nagykery NG; Leung EY; Khelghati B; Geula C
Brain Res; 2005 Oct; 1060(1-2):144-52. PubMed ID: 16212945
[TBL] [Abstract][Full Text] [Related]
9. Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Doody RS
J Clin Psychiatry; 2003; 64 Suppl 9():11-7. PubMed ID: 12934969
[TBL] [Abstract][Full Text] [Related]
10. Potential therapeutic natural products against Alzheimer's disease with Reference of Acetylcholinesterase.
Ahmed S; Khan ST; Zargaham MK; Khan AU; Khan S; Hussain A; Uddin J; Khan A; Al-Harrasi A
Biomed Pharmacother; 2021 Jul; 139():111609. PubMed ID: 33915501
[TBL] [Abstract][Full Text] [Related]
11. Switching cholinesterase inhibitors in patients with Alzheimer's disease.
Emre M
Int J Clin Pract Suppl; 2002 Jun; (127):64-72. PubMed ID: 12139369
[TBL] [Abstract][Full Text] [Related]
12. Screening of non-alkaloidal natural compounds as acetylcholinesterase inhibitors.
Brühlmann C; Marston A; Hostettmann K; Carrupt PA; Testa B
Chem Biodivers; 2004 Jun; 1(6):819-29. PubMed ID: 17191882
[TBL] [Abstract][Full Text] [Related]
13. Naturally Occurring Cholinesterase Inhibitors from Plants, Fungi, Algae, and Animals: A Review of the Most Effective Inhibitors Reported in 2012-2022.
Murray AP; Biscussi B; Cavallaro V; Donozo M; Rodriguez SA
Curr Neuropharmacol; 2024; 22(10):1621-1649. PubMed ID: 37357520
[TBL] [Abstract][Full Text] [Related]
14. A Current Perspective on the Inhibition of Cholinesterase by Natural and Synthetic Inhibitors.
Shah AA; Dar TA; Dar PA; Ganie SA; Kamal MA
Curr Drug Metab; 2017; 18(2):96-111. PubMed ID: 27890007
[TBL] [Abstract][Full Text] [Related]
15. GC/MS analysis of three Amaryllidaceae species and their cholinesterase activity.
Cahlíková L; Benesová N; Macákova K; Urbanová K; Opletal L
Nat Prod Commun; 2011 Sep; 6(9):1255-8. PubMed ID: 21941892
[TBL] [Abstract][Full Text] [Related]
16. 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.
Schott Y; Decker M; Rommelspacher H; Lehmann J
Bioorg Med Chem Lett; 2006 Nov; 16(22):5840-3. PubMed ID: 16945529
[TBL] [Abstract][Full Text] [Related]
17. Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.
Samadi A; de los Ríos C; Bolea I; Chioua M; Iriepa I; Moraleda I; Bartolini M; Andrisano V; Gálvez E; Valderas C; Unzeta M; Marco-Contelles J
Eur J Med Chem; 2012 Jun; 52():251-62. PubMed ID: 22503231
[TBL] [Abstract][Full Text] [Related]
18. A review on cholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B
Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
[TBL] [Abstract][Full Text] [Related]
19. Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles.
Mesulam MM; Geula C; Morán MA
Ann Neurol; 1987 Dec; 22(6):683-91. PubMed ID: 3435078
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
